ALT Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -463600% compared to Altimmune's net margin of 32.59%. Altimmune's return on equity of -61.21% beat Eli Lilly and's return on equity of 80.24%.

Altimmune has a consensus price target of $22.38, signalling upside risk potential of 428.96%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.63 which suggests that it could grow by 34.09%. Given that Altimmune has higher upside potential than Eli Lilly and, analysts believe Altimmune is more attractive than Eli Lilly and.

Altimmune has a beta of 0.907, which suggesting that the stock is 9.323% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Altimmune pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Altimmune quarterly revenues are $5K, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Altimmune's net income of -$23.2M is lower than Eli Lilly and's net income of $4.4B. Notably, Altimmune's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 15,018.76x versus 15.13x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -463600% compared to Altimmune's net margin of 2.31%. Altimmune's return on equity of -61.21% beat Pfizer's return on equity of 8.91%.

Altimmune has a consensus price target of $22.38, signalling upside risk potential of 428.96%. On the other hand Pfizer has an analysts' consensus of $30.73 which suggests that it could grow by 36.66%. Given that Altimmune has higher upside potential than Pfizer, analysts believe Altimmune is more attractive than Pfizer.

Altimmune has a beta of 0.907, which suggesting that the stock is 9.323% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.52% to investors and pays a quarterly dividend of $0.43 per share. Altimmune pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are smaller than Pfizer quarterly revenues of $17.8B. Altimmune's net income of -$23.2M is lower than Pfizer's net income of $410M. Notably, Altimmune's price-to-earnings ratio is -- while Pfizer's PE ratio is 15.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 15,018.76x versus 2.01x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals has a net margin of -463600% compared to Altimmune's net margin of --. Altimmune's return on equity of -61.21% beat Terns Pharmaceuticals's return on equity of --.

Altimmune has a consensus price target of $22.38, signalling upside risk potential of 428.96%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.06 which suggests that it could grow by 728.8%. Given that Terns Pharmaceuticals has higher upside potential than Altimmune, analysts believe Terns Pharmaceuticals is more attractive than Altimmune.

Altimmune has a beta of 0.907, which suggesting that the stock is 9.323% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Terns Pharmaceuticals quarterly revenues of --. Altimmune's net income of -$23.2M is lower than Terns Pharmaceuticals's net income of -$21.8M. Notably, Altimmune's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 15,018.76x versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -463600% compared to Altimmune's net margin of --. Altimmune's return on equity of -61.21% beat Viking Therapeutics's return on equity of --.

Altimmune has a consensus price target of $22.38, signalling upside risk potential of 428.96%. On the other hand Viking Therapeutics has an analysts' consensus of $95.44 which suggests that it could grow by 313.18%. Given that Altimmune has higher upside potential than Viking Therapeutics, analysts believe Altimmune is more attractive than Viking Therapeutics.

Altimmune has a beta of 0.907, which suggesting that the stock is 9.323% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Viking Therapeutics quarterly revenues of --. Altimmune's net income of -$23.2M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Altimmune's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 15,018.76x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.